Kimberly-Clark Tanks on Deal to Buy Tylenol Maker Kenvue

Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Redd Brown and Crystal Tse

November 3, 2025 at 11:50 AM UTC

Updated on

November 3, 2025 at 8:30 PM UTC

Kimberly-Clark Corp. shares fell the most in a quarter century after agreeing to buy Kenvue Inc., whose biggest product, Tylenol, is in the crosshairs of the White House.

Kimberly-Clark said it would buy Kenvue for roughly $40 billion, snapping up the embattled company’s storied brands in a gamble that would vault the Kleenex owner into consumer health’s top tier. Kimberly-Clark agreed to pay a total consideration of $21.01 per share, a 46% premium to Kenvue’s closing price on Friday.